188 related articles for article (PubMed ID: 14679923)
1. Failure of combination abacavir + tenofovir + lamivudine (3TC).
AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
[TBL] [Abstract][Full Text] [Related]
2. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Becker S; Feinberg J
AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
[TBL] [Abstract][Full Text] [Related]
3. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Albrecht H
AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
[No Abstract] [Full Text] [Related]
4. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Feinberg J
AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
[No Abstract] [Full Text] [Related]
5. Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.
James JS
AIDS Treat News; 2005; (416):5-6. PubMed ID: 16388545
[TBL] [Abstract][Full Text] [Related]
6. Early nonresponse for tenofovir regimen.
AIDS Patient Care STDS; 2003 Nov; 17(11):603. PubMed ID: 14748354
[No Abstract] [Full Text] [Related]
7. High rate of virologic failure with once-daily ddI/3TC/TDF.
IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
[No Abstract] [Full Text] [Related]
8. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Kuritzkes DR
J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
[No Abstract] [Full Text] [Related]
9. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
Berger DS
Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
[No Abstract] [Full Text] [Related]
10. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Bayonne Kombo ES; Gathse A
Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
[No Abstract] [Full Text] [Related]
11. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
[TBL] [Abstract][Full Text] [Related]
12. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
[TBL] [Abstract][Full Text] [Related]
13. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Hoogewerf M; Regez RM; Schouten WE; Weigel HM; Frissen PH; Brinkman K
Lancet; 2003 Dec; 362(9400):1979-80. PubMed ID: 14683659
[TBL] [Abstract][Full Text] [Related]
14. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Stürmer M; Staszewski S; Doerr HW
Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
[TBL] [Abstract][Full Text] [Related]
15. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Khanlou H; Farthing C
AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
[No Abstract] [Full Text] [Related]
17. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
18. Impact of tenofovir versus abacavir on HIV-related endothelial dysfunction.
Francisci D; Falcinelli E; Belfiori B; Petito E; Fierro T; Baldelli F; Gresele P
AIDS Patient Care STDS; 2011 Oct; 25(10):567-9. PubMed ID: 21851265
[No Abstract] [Full Text] [Related]
19. Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.
Hicks CB
AIDS Clin Care; 2009 Jan; 21(1):3. PubMed ID: 19219957
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate (Viread).
Porche DJ
J Assoc Nurses AIDS Care; 2002; 13(3):100-2. PubMed ID: 12064015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
